Zacks.com on MSN2d
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Abbott's Still Crushing It
Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...
Forbes18d
Why Abbott Stock Looks More Attractive Than Its Medical Devices Peer
Given its better prospects, we believe Abbott stock (NYSE: ABT) is a better pick than its peer Medtronic stock (NYSE: MDT). ABT stock trades at 4.9x trailing revenues, versus 3.6x for MDT.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
Hosted on MSN1d
Here's Why Abbott (ABT) Fell More Than Broader Market
In the latest market close, Abbott (ABT) reached $113.70, with a -0.39% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a rise ...
Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...